首页> 外文期刊>The Journal of Pharmacology and Experimental Therapeutics: Official Publication of the American Society for Pharmacology and Experimental Therapeutics >Glucuronidation Converting Methyl 1-(3,4-Dimethoxyphenyl)-3-(3-ethylvaleryl)-4-hydroxy-6,7,8-trimethoxy-2-naphthoate(S-8921)to a Potent Apical Sodium-Dependent Bile Acid Transporter Inhibitor,Resulting in a Hypocholesterolemic Action
【24h】

Glucuronidation Converting Methyl 1-(3,4-Dimethoxyphenyl)-3-(3-ethylvaleryl)-4-hydroxy-6,7,8-trimethoxy-2-naphthoate(S-8921)to a Potent Apical Sodium-Dependent Bile Acid Transporter Inhibitor,Resulting in a Hypocholesterolemic Action

机译:葡萄糖醛酸化作用将1-(3,4-二甲氧基苯基)-3-(3-乙基戊酰基)-4-羟基-6,7,8-三甲氧基-2-萘甲酸甲酯(S-8921)转化为有效的根尖钠依赖性胆汁酸转运蛋白抑制剂,导致降胆固醇

获取原文
获取原文并翻译 | 示例
           

摘要

Methyl 1-(3,4-dimethoxyphenyl)-3-(3-ethylvaleryl)-4-hydroxy-6,7,8-trimethoxy-2-naphthoate(S-8921)is a novel inhibitor of the ileal apical sodium-dependent bile acid transporter(ASBT/SLC10A2)developed for the treatment of hypercholesterolemia.The present study investigated the hypocholesterolemic action of S-8921 glucuronide(S-8921G)in rats.The plasma concentration of S-8921G was higher than that of S-8921 after single oral administration of S-8921 in normal rats,and S-8921G was excreted into the bile(13% dose).Oral administration of either S-8921 or S-8921G reduced the serum total cholesterol,particularly nonhigh-density lipoprotein cholesterol,in hypercholesterolemic normal rats.In Gunn rats devoid of UDP glucuronosyltransferase-1A activity,S-8921G was undetectable both in the plasma and bile specimens,and only S-8921G administration significantly reduced the serum non-high-density lipoprotein cholesterol.An in vitro inhibition study showed that glucuronidation converts S-8921 to a 6000-fold more potent inhibitor of human ASBT(K_i,=18 nM versus 109 mu M).S-8921G was detected both in the portal plasma and loop when S-8921 was administered into the loop of the rat jejunum,although the cumulative amount of S-8921G recovered in the bile was 5-fold greater than that in the loop.The uptake of S-8921G by freshly prepared rat hepatocytes was saturable,and sodium-dependent and-independent systems were involved.Organic anions,such as bromosulfophthalein,estrone 3-sulfate,and taurocholic acid,inhibited the uptake.These results suggest that UDP glucuronosyltransferase-1 isoforms play a critical role in the hypocholesterolemic action of S-8921 by converting S-8921 to a more potent ASBT inhibitor,and organic anion transporter(s)are also involved in its pharmacological action through the biliary excretion of S-8921G.
机译:1-(3,4-二甲氧基苯基)-3-(3-乙基戊基)-4-羟基-6,7,8-三甲氧基-2-萘甲酸甲酯(S-8921)是一种回肠末端钠依赖性的新型抑制剂胆汁酸转运蛋白(ASBT / SLC10A2)用于治疗高胆固醇血症。本研究探讨了S-8921葡糖醛酸(S-8921G)在大鼠体内的降胆固醇作用,S-8921G的血浆浓度高于S-8921正常大鼠单次口服S-8921后,将S-8921G排入胆汁(13%剂量)。口服S-8921或S-8921G会降低血清总胆固醇,特别是非高密度脂蛋白胆固醇在没有UDP葡萄糖醛糖苷转移酶-1A活性的Gunn大鼠中,血浆和胆汁标本中均未检测到S-8921G,只有施用S-8921G才能显着降低血清非高密度脂蛋白胆固醇。体外抑制研究表明,葡萄糖醛酸苷化作用可将S-8921转化为60将人ASBT抑制剂的效价提高了00倍(K_i,= 109 nM,相对于109μM为18 nM)。当将S-8921注入大鼠空肠环中时,在门静脉血浆和环中均检测到S-8921G胆汁中回收的S-8921G量比环中多5倍。新鲜制备的大鼠肝细胞对S-8921G的吸收是饱和的,并且涉及钠依赖性和非依赖性系统。结果表明,UDP葡萄糖醛酸转移酶-1亚型通过将S-8921转化为更有效的ASBT抑制剂和有机物,在S-8921的降胆固醇作用中起关键作用。阴离子转运蛋白还通过S-8921G的胆汁排泄参与其药理作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号